OLFM4 and neoplasm: In summary, our findings establish OLFM4 as a critical oncogenic driver in HNSCC progression and prognosis, demonstrating that its upregulation promotes tumor aggressiveness through enhanced proliferation, migratory, and invasive capacities while simultaneously conferring cisplatin resistance.